These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 36277428)

  • 1. Urinary brain-derived neurotrophic factor and nerve growth factor as noninvasive biomarkers of overactive bladder in children.
    Colic M; Rogic D; Lenicek Krleza J; Kozmar A; Stemberger Maric L; Abdovic S
    Biochem Med (Zagreb); 2022 Oct; 32(3):030706. PubMed ID: 36277428
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Urinary brain-derived neurotrophic factor: a potential biomarker for objective diagnosis of overactive bladder.
    Wang LW; Han XM; Chen CH; Ma Y; Hai B
    Int Urol Nephrol; 2014 Feb; 46(2):341-7. PubMed ID: 23982767
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nerve Growth Factor and Brain-Derived Neurotrophic Factor as Potential Biomarkers of Mirabegron Efficacy in Patients with Overactive Bladder Syndrome.
    Beta A; Giannouli A; Rizos D; Mantzou A; Deligeoroglou E; Bakas P
    Int Urogynecol J; 2024 Jun; 35(6):1317-1322. PubMed ID: 38761233
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Can Urinary Nerve Growth Factor and Brain-Derived Neurotrophic Factor be used in the Diagnosis and Follow-Up of Voiding Dysfunction in Children?
    Özdemir K; Dinçel N; Berdeli A; Mir S
    Urol J; 2016 Jun; 13(3):2690-6. PubMed ID: 27351324
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Urinary Nerve Growth Factor Can Predict Therapeutic Efficacy in Children With Overactive Bladder.
    Fukui S; Aoki K; Morizawa Y; Miyake M; Fujimoto K
    Urology; 2017 May; 103():214-217. PubMed ID: 28161379
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The profile of urinary biomarkers in overactive bladder.
    Rada MP; Ciortea R; Măluţan AM; Doumouchtsis SK; Bucuri CE; Clim A; Roman A; Mihu D
    Neurourol Urodyn; 2020 Nov; 39(8):2305-2313. PubMed ID: 32813897
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Urinary neurotrophic peptides in postmenopausal women with and without overactive bladder.
    Pennycuff JF; Schutte SC; Hudson CO; Karp DR; Malykhina AP; Northington GM
    Neurourol Urodyn; 2017 Mar; 36(3):740-744. PubMed ID: 27062604
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of urinary biomarkers in the diagnosis of overactive bladder in female patients. A systematic review and meta-analysis.
    Tsiapakidou S; Apostolidis A; Pantazis K; Grimbizis GF; Mikos T
    Int Urogynecol J; 2021 Dec; 32(12):3143-3155. PubMed ID: 34363496
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Urinary nerve growth factor in children with overactive bladder: a promising, noninvasive and objective biomarker.
    Oktar T; Kocak T; Oner-Iyidogan Y; Erdem S; Seyithanoglu M; Ziylan O; Kocak H
    J Pediatr Urol; 2013 Oct; 9(5):617-21. PubMed ID: 22789557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Could urinary nerve growth factor and bladder wall thickness predict the treatment outcome of children with overactive bladder?
    Huseynov A; Telli O; Haciyev P; Okutucu TM; Akinci A; Ozkidik M; Erguder I; Fitoz S; Burgu B; Soygur T
    Int Braz J Urol; 2022; 48(3):553-560. PubMed ID: 35373950
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of biomarkers in the diagnosis and treatment of overactive bladder: Can we predict the patients who will be resistant to treatment?
    Alkis O; Zumrutbas AE; Toktas C; Aybek H; Aybek Z
    Neurourol Urodyn; 2017 Feb; 36(2):390-393. PubMed ID: 26661444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Urinary nerve growth factor and a variable solifenacin dosage in patients with an overactive bladder.
    Ciftci S; Ozkurkcugil C; Yilmaz H; Ustuner M; Yavuz U; Yuksekkaya M; Cekmen MB
    Int Urogynecol J; 2016 Feb; 27(2):275-80. PubMed ID: 26310546
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Urinary neurotrophic factors in healthy individuals and patients with overactive bladder.
    Antunes-Lopes T; Pinto R; Barros SC; Botelho F; Silva CM; Cruz CD; Cruz F
    J Urol; 2013 Jan; 189(1):359-65. PubMed ID: 23174241
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel biomarkers of overactive bladder syndrome.
    Wróbel AF; Kluz T; Surkont G; Wlaźlak E; Skorupski P; Filipczak A; Rechberger T
    Ginekol Pol; 2017; 88(10):568-573. PubMed ID: 29192418
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Urinary Neurotrophin Levels Increase in Women With Stress Urinary Incontinence After a Midurethral Sling Procedure.
    Antunes-Lopes T; Coelho A; Pinto R; Barros SC; Cruz CD; Cruz F; Silva CM
    Urology; 2017 Jan; 99():49-56. PubMed ID: 27697460
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NGF and HB-EGF: potential biomarkers that reflect the effects of fesoterodine in patients with overactive bladder syndrome.
    Kim SR; Moon YJ; Kim SK; Bai SW
    Yonsei Med J; 2015 Jan; 56(1):204-11. PubMed ID: 25510766
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Could urinary nerve growth factor be a biomarker for overactive bladder? A meta-analysis.
    Sheng W; Zhang H; Ruth KH
    Neurourol Urodyn; 2017 Sep; 36(7):1703-1710. PubMed ID: 28102552
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decrease of urinary nerve growth factor but not brain-derived neurotrophic factor in patients with interstitial cystitis/bladder pain syndrome treated with hyaluronic acid.
    Jiang YH; Liu HT; Kuo HC
    PLoS One; 2014; 9(3):e91609. PubMed ID: 24614892
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nerve growth factor (NGF): a potential urinary biomarker for overactive bladder syndrome (OAB)?
    Seth JH; Sahai A; Khan MS; van der Aa F; de Ridder D; Panicker JN; Dasgupta P; Fowler CJ
    BJU Int; 2013 Mar; 111(3):372-80. PubMed ID: 23444927
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Urinary nerve growth factor can predict therapeutic efficacy in children with monosymptomatic nocturnal enuresis.
    Morizawa Y; Aoki K; Iemura Y; Hori S; Gotoh D; Fukui S; Nakai Y; Miyake M; Torimoto K; Tanaka N; Fujimoto K
    Neurourol Urodyn; 2019 Nov; 38(8):2311-2317. PubMed ID: 31432572
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.